Brief: Simris Biologics Awarded EUR 0.2 Mln Funding For R&D Programme
Sept 12 (Reuters) - Simris Group AB SIMRISb.ST: SIMRIS BIOLOGICS AWARDED EUR 200K IN NON-DILUTIVE FUNDING FOR RESEARCH AND DEVELOPMENT PROGRAMME TO FURTHER DEVELOP MICROCYSTIN PAYLOADS FOR ANTIBODY DRUG CONJUGATES (ADCS) GRANT PROVIDES EUR 201K TO SIMRIS AND EUR 186K TO FREIE UNIVERSITÄT BERLIN OVER THREE YEARS, STARTING SEPTEMBER 1, 2025 Source text: ID:nMFN1BhXX4 Further company coverage: [SIMRISb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Simris AB
See all newsSweden's Simris Alg Q1 revenue jumps 167%, losses narrow
Brief: Simris Alg Q1 Revenue SEK 424 Thousand
Brief: Simris Group Advances Asset Divestment Process With Two Prospective Buyers
Brief: Simris Evaluating Options To Expand Its ADC-Payload Development Programme
Brief: Simris Updates On Divestment Of Its Assets